FDA panel expresses concern over OTC OAB patch


Merck has confirmed that the FDA Nonprescription Drug Advisory Committee proposed that the FDA consider labeling modifications as part of its review of oxybutynin transdermal system (Oxytrol) as an over-the-counter treatment for overactive bladder in women.

Related Videos
Samuel L. Washington III, MD, answers a question during a Zoom video interview
blurred image of a clinic hallway
Dr. Kyle A. Richards in an interview with Urology Times
Expert on OAB
Experts on OAB
Expert on OAB
3d rendered illustration - bladder cancer | Image Credit: © SciePro - stock.adobe.com
stethoscope on laptop keyboard
Related Content
© 2023 MJH Life Sciences

All rights reserved.